目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Peptide Drug Conjugates Market Variables, Trends, & Scope
3.1. Parent Market Outlook
3.2. Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market drivers analysis
3.3.1.1. Rising prevalence of neurological disorders increasing disease prevalence
3.3.1.2. Robust clinical trial pipeline
3.3.1.3. Growing focus on targeted drug delivery
3.3.2. Market Restraints Analysis
3.3.2.1. Long R&D time and slow clinical development process
3.3.2.2. Stringent regulations associated with peptide drug conjugates (PDC’s)
3.4. Dopamine Agonist Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
3.5. Pipeline Analysis
3.5.1. Phase 1
3.5.2. Phase 2
3.5.3. Phase 3

Chapter 4. Peptide Drug Conjugates Market: By Product Estimates & Trend Analysis
4.1. Peptide Drug Conjugates Market: Product Segment Dashboard
4.2. Peptide Drug Conjugates Market: By Product Movement Analysis, 2024 & 2030 (USD Million)
4.3. Illuccix
4.3.1. Illuccix Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Pluvicto
4.4.1. Pluvicto Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Lutathera
4.5.1. Lutathera Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. OctreoScan
4.6.1. OctreoScan Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Others
4.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Peptide Drug Conjugates Market: Type Estimates & Trend Analysis
5.1. Peptide Drug Conjugates Market: Type Segment Dashboard
5.2. Peptide Drug Conjugates Market: By Type Movement Analysis, 2024 & 2030 (USD Million)
5.3. Therapeutics
5.3.1. Therapeutics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Diagnostics
5.4.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Peptide Drug Conjugates Market: Regional Estimates & Trend Analysis
6.1. Peptide Drug Conjugates Market Share, By Region, 2024 & 2030, USD Million
6.2. North America
6.2.1. North America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Target Disease Prevalence
6.2.2.3. Regulatory Framework
6.2.2.4. Reimbursement Framework
6.2.2.5. U.S. Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Regulatory Framework
6.2.3.4. Reimbursement Framework
6.2.3.5. Canada Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.4. Mexico
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Regulatory Framework
6.2.4.4. Reimbursement Framework
6.2.4.5. Mexico Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. Europe Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2. UK
6.3.2.1. Key Country Dynamics
6.3.2.2. Target Disease Prevalence
6.3.2.3. Regulatory Framework
6.3.2.4. Reimbursement Framework
6.3.2.5. Uk Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Regulatory Framework
6.3.3.4. Reimbursement Framework
6.3.3.5. Germany Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Regulatory Framework
6.3.4.4. Reimbursement Framework
6.3.4.5. France Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.5. Italy
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Regulatory Framework
6.3.5.4. Reimbursement Framework
6.3.5.5. Italy Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.6. Spain
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Regulatory Framework
6.3.6.4. Reimbursement Framework
6.3.6.5. Spain Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Regulatory Framework
6.3.7.4. Reimbursement Framework
6.3.7.5. Denmark Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Regulatory Framework
6.3.8.4. Reimbursement Framework
6.3.8.5. Sweden Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.9. Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Regulatory Framework
6.3.9.4. Reimbursement Framework
6.3.9.5. Norway Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. Japan Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. China
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. China Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. India Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.5. Australia
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Regulatory Framework
6.4.5.4. Reimbursement Framework
6.4.5.5. Australia Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.6. South Korea
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Regulatory Framework
6.4.6.4. Reimbursement Framework
6.4.6.5. South Korea Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.7. Thailand
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Regulatory Framework
6.4.7.4. Reimbursement Framework
6.4.7.5. Thailand Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. Japan Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Argentina
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. China Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Middle East and Africa
6.6.1. Middle East and Africa Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. South Africa Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. Saudi Arabia
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. Saudi Arabia Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. UAE Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Kuwait Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Categorization
7.3. Participant Overview
7.4. Financial Performance
7.5. Product Bench Marking
7.6. Company Market Share Analysis, 2024
7.7. Company Profiles
7.7.1. Novartis AG
7.7.1.1. Participant’s Overview
7.7.1.2. Financial Performance
7.7.1.3. Product Benchmarking
7.7.1.4. Recent Developments/ Strategic Initiatives
7.7.2. AstraZeneca
7.7.2.1. Participant’s Overview
7.7.2.2. Financial Performance
7.7.2.3. Product Benchmarking
7.7.2.4. Recent Developments/ Strategic Initiatives
7.7.3. Oncopeptides AB
7.7.3.1. Participant’s Overview
7.7.3.2. Financial Performance
7.7.3.3. Product Benchmarking
7.7.3.4. Recent Developments/ Strategic Initiatives
7.7.4. Bicycle Therapeutics
7.7.4.1. Participant’s Overview
7.7.4.2. Financial Performance
7.7.4.3. Product Benchmarking
7.7.4.4. Recent Developments/ Strategic Initiatives
7.7.5. Cybrexa
7.7.5.1. Participant’s Overview
7.7.5.2. Financial Performance
7.7.5.3. Product Benchmarking
7.7.5.4. Recent Developments/ Strategic Initiatives
7.7.6. Angiochem Inc.
7.7.6.1. Participant’s Overview
7.7.6.2. Financial Performance
7.7.6.3. Product Benchmarking
7.7.6.4. Recent Developments/ Strategic Initiatives
7.7.7. Soricimed Biopharma
7.7.7.1. Participant’s Overview
7.7.7.2. Financial Performance
7.7.7.3. Product Benchmarking
7.7.7.4. Recent Developments/ Strategic Initiatives
7.7.8. Theratechnologies Inc.
7.7.8.1. Participant’s Overview
7.7.8.2. Financial Performance
7.7.8.3. Product Benchmarking
7.7.8.4. Recent Developments/ Strategic Initiatives

Chapter 8. Conclusion

List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 List of Parameters
Table 4 List of Distributors
Table 5 Global Peptide Drug Conjugates Market, By Region, 2018 - 2030 (USD Million)
Table 6 Global Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 7 Global Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 8 North America Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 9 North America Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 10 North America Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 11 U.S. Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 12 U.S. Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 13 Canada Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 14 Canada Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 15 Mexico Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 16 Mexico Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 17 Europe Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 18 Europe Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 19 Europe Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 20 Germany Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 21 Germany Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 22 UK Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 23 UK Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 24 France Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 25 France Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 26 Italy Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 27 Italy Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 28 Spain Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 29 Spain Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 30 Denmark Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 31 Denmark Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 32 Sweden Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 33 Sweden Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 34 Norway Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 35 Norway Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 36 Asia Pacific Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 37 Asia Pacific Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 38 Asia Pacific Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 39 Japan Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 40 Japan Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 41 China Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 42 China Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 43 India Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 44 India Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 45 South Korea Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 46 South Korea Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 47 Australia Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 48 Australia Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 49 Thailand Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 50 Thailand Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 51 Latin America Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 52 Latin America Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 53 Latin America Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 54 Brazil Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 55 Brazil Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 56 Argentina Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 57 Argentina Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 58 Middle East & Africa Peptide Drug Conjugates Market, By Country, 2018 - 2030 (USD Million)
Table 59 Middle East & Africa Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 60 Middle East & Africa Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 61 Saudi Arabia Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 62 Saudi Arabia Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 63 South Africa Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 64 South Africa Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 65 UAE Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 66 UAE Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)
Table 67 Kuwait Peptide Drug Conjugates Market, By Product, 2018 - 2030 (USD Million)
Table 68 Kuwait Peptide Drug Conjugates Market, By Type, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Peptide drug conjugates market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Product and type segment snapshot
Fig. 10 Competitive landscape snapshot
Fig. 11 Peptide therapeutics market value, 2024 (USD billion)
Fig. 12 Market dynamics
Fig. 13 Global number of new cases caused by top 11 cancer types in 2023 (in thousands)
Fig. 14 Porter's five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Peptide Drug Conjugates market: Product outlook and key takeaways
Fig. 17 Peptide drug conjugates market: Product movement analysis
Fig. 18 Lutathera market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 OctreoScan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Illuccix market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Pluvicto market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Peptide drug conjugates market: Type outlook and key takeaways
Fig. 24 Peptide drug conjugates market: Type movement analysis
Fig. 25 Therapeutic market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Diagnostic market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Peptide drug conjugates market revenue, by region, 2024 & 2030 (USD Million)
Fig. 28 Regional marketplace: Key takeaways
Fig. 29 North America peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Key country dynamics
Fig. 31 U.S. peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Key country dynamics
Fig. 33 Canada peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Key country dynamics
Fig. 35 Mexico peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Europe peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Key country dynamics
Fig. 38 UK peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Key country dynamics
Fig. 40 Germany peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Key country dynamics
Fig. 42 France peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Key country dynamics
Fig. 44 Italy peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Key country dynamics
Fig. 46 Spain peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Key country dynamics
Fig. 48 Denmark peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Key country dynamics
Fig. 50 Sweden peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Key country dynamics
Fig. 52 Norway peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Rest of Europe peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Asia Pacific peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Key country dynamics
Fig. 56 Japan peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 China peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Key country dynamics
Fig. 60 India peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Key country dynamics
Fig. 62 Australia peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 Thailand peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Key country dynamics
Fig. 66 South Korea peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Rest of Asia Pacific peptide drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Latin America peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 Key country dynamics
Fig. 70 Brazil peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Key country dynamics
Fig. 72 Argentina peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Rest of Latin America peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 MEA peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Key country dynamics
Fig. 76 South Africa peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 Saudi Arabia peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Key country dynamics
Fig. 80 UAE peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Key country dynamics
Fig. 82 Kuwait peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Rest of MEA peptide drug conjugates market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Company/competition categorization
Fig. 85 Company market share analysis, 2024
Fig. 86 Strategy mapping